MDS-L-2007 cell line is a blastic subline originated from MDS-L. (MDS-L cell line is a blastic subline derived from MDS92 which was established from the bone marrow of a patient with MDS.) MDS-L-2007 cells proliferate in the presence of IL-3 and have lost maturing capacity.
Terms and conditions
1) TheRECIPIENT of BIOLOGICAL RESOURCE shall obtain a priorcon sent on use of it from the DEVELOPER and DEPOSITOR. The RECIPIENT shall conclude a MTA with the depositor. 2) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature (Leukemia 2018 32(8):1846-1850) designated by the DEPOSITOR is requested. 3) In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Remarks
approver's address
×
English
Address
Kawasaki University of Medical Welfare Industry-Academia Collaboration and Intellectual Property Management Section 577 Matsushima, Kurashiki-city, Okayama 701-0192 JAPAN E-mail. s-renkei@med.kawasaki-m.ac.jp
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information
Depositor
TOHYAMA, Kaoru
Originator
TOHYAMA, Kaoru
Year of deposit
2022
Another name
MDS-L2007
Cloning (depositor)
No
Animal
_human
< Mammals
Genus
Homo
Species
sapiens
Race
Japanese
Gender
Male
Age at sampling
54 years
Tissue
bone marrow
Primary focus
bone marrow
Disease name
myelodysplastic syndrome (MDS)
Tumor
MDS-EB1 stage from MDS-RS
Classification
cancer
Recombinant
non-recombinant
Year of origin
1991
Memo_1
splice donor site mutation of TP53 (c.672+1G>A; homozygous; COSM6906) NRAS (G12A) mutation (heterozygous; COSM565) CEBPA (Q311stop) mutation (heterozygous; COSM29221) HIST1H3C (K27M) mutation (heterozygous; COSM1580151) in all the cells
Lifespan
infinite
Morphology
lymphocyte-like
Differentiation
Whole cells retain immature blastic features and differentiation-induction is successful at present.
As a reference, the main karyotype of the parental MDS-L cell line is: 49, XY, +1, der(5)t(5;19), -7, +8, -12, der(13)t(7;13), der(14)t(12;14), der(15)t(15;15), -17, +19, +20, der(21)t(15;21), der(22)t(11;22).
17050
Shafiee S, Gelebart P, Popa M, Hellesøy M, Hovland R, Brendsdal Forthun R, Lee J, Tohyama K, Molven A, Parekkadan B, Tore Gjertsen B, Olsnes Kittang A, McCormack E.
Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell lineBr J Haematol
2021
193(2):415-419
PubMed ID: 33686650
DOI: 10.1111/bjh.17372
17048
Kida JI, Tsujioka T, Suemori SI, Okamoto S, Sakakibara K, Takahata T, Yamauchi T, Kitanaka A, Tohyama Y, Tohyama K.
An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDSLeukemia
2018
32(8):1846-1850
PubMed ID: 29955132
DOI: 10.1038/s41375-018-0189-7
Back
Top
CELL BANK Website
How_to_culture_MDS-L_and_MDS-L-2007.pdf